Pfizer’s abrocitinib meets all endpoints in JADE MONO-1 study

Pfizer’s abrocitinib demonstrates significant skin clearance in atopic dermatitis trial. Credit: Lauri Silvennoinen.



  • Pfizer’s abrocitinib meets all endpoints in JADE MONO-1 study